(Q36618096)

English

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

scientific article published on February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

phase III clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

20

object named as

Lawrence Corey

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

object named as

M Juliana McElrath

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

object named as

Guido Ferrari

8

0 references

David C. Montefiori

7

object named as

David C Montefiori

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Barney S. Graham

2

object named as

Barney S Graham

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lindsey R Baden

17

object named as

Lindsey R Baden

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

19

object named as

Beryl A Koblin

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Susan Buchbinder

16

object named as

Susan P Buchbinder

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Mark J Mulligan

14

object named as

Mark J Mulligan

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Georgia D. Tomaras

10

object named as

Georgia D Tomaras

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Nina D. Russell

1

object named as

Nina D Russell

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kent J. Weinhold

6

object named as

Kent J Weinhold

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

13

object named as

Sharon E Frey

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

5

object named as

Steve G Self

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Michael C Keefer

3

object named as

Michael C Keefer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clayton D Harro

15

object named as

Clayton D Harro

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Helen Horton

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sanjay Gurunathan

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lynn Baglyos

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

William A Blattner

18

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network

21

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Journal of Acquired Immune Deficiency Syndromes

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

44

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

203-212

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

The new numerology of immunity mediated by virus-specific CD8(+) T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

30 September 2017

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

28 June 2018

Rapid effector function in CD8+ memory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

28 June 2018

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362395

20 September 2018

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/17106277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/17106277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17106277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17106277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA-peptide tetrameric complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17106277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/01.QAI.0000248356.48501.FF

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36618096&oldid=1857462810"